Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen ; volume:38 ; number:1 ; day:1 ; month:7 ; year:2023 ; pages:161-167 ; date:1.2024
Eye ; 38, Heft 1 (1.7.2023), 161-167, 1.2024
- Urheber
-
Cozzi, Mariano
Monteduro, Davide
Esposito, Raffaele Antonio
Spooner, Kimberly L.
Fraser-Bell, Samantha
Staurenghi, Giovanni
Romano, Francesco
Airaldi, Matteo
Chang, Andrew A.
Invernizzi, Alessandro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-023-02652-3
- URN
-
urn:nbn:de:101:1-2024031814260439856809
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cozzi, Mariano
- Monteduro, Davide
- Esposito, Raffaele Antonio
- Spooner, Kimberly L.
- Fraser-Bell, Samantha
- Staurenghi, Giovanni
- Romano, Francesco
- Airaldi, Matteo
- Chang, Andrew A.
- Invernizzi, Alessandro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Near-infrared reflectance imaging of neovascular age-related macular degeneration